Retatrutide in Australia: how to buy and verify it

Retatrutide (LY-3437943) is a triple GLP-1/GIP/glucagon agonist still in clinical trials. Almost every vial sold in Australia is grey-market, and our lab data shows a meaningful share fails identity, purity, or content checks. This guide is what we tell our own customers before they order.

Why retatrutide is the highest-risk peptide right now

Retatrutide isn't approved anywhere: there is no pharmaceutical reference batch, no PBS listing, and no compounding pharmacy producing it legitimately for Australian patients. Every vial in circulation comes from a research-chemical supplier, and the molecule is expensive enough to synthesise that under-dosing and outright substitution with tirzepatide are common.

Across the LabDoc dataset, retatrutide has one of the lowest pass rates of any peptide we aggregate, typically driven by under-fill (vial contains less peptide than labelled) rather than impurity.

What a real retatrutide CoA shows

• Identity by LC-MS matching the retatrutide monoisotopic mass (~4731 Da).
• HPLC purity ≥ 95%, with a clean main peak and no twin peak near the retention time of tirzepatide or semaglutide.
• Quantitative HPLC peptide content within ±10% of the labelled mg per vial.
• A batch number that matches the sticker on your vial and a date within the last 6 months.

The four most common ways retatrutide vials fail

1. Under-fill. Labelled 10 mg, contains 6-7 mg. Most common failure mode.
2. Tirzepatide substitution. The vial is real peptide, just not the peptide on the label. Caught by identity testing.
3. Mixed batch. Two peaks on HPLC at similar retention times, usually retatrutide cut with a cheaper GLP-1.
4. Stale CoA. Vendor reuses one CoA across multiple batches; the batch number on your vial doesn't appear on the report.

How to verify before injecting

1. Ask the vendor for the CoA for your specific batch number, not a generic product CoA.
2. Check retatrutide purity test results for that vendor on LabDoc.
3. If your vendor isn't on Verified, send a vial for independent testing. A$549 covers identity, purity and content.

Pricing reality check

If a vendor is selling 10 mg retatrutide for noticeably less than the prevailing market rate, expect under-fill. There is no legitimate cost advantage at this dose. The active ingredient is the dominant input cost.